Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2024-01-26 Director's Dealing
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-01-26 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-01-26 English
SC 13G/A
Major Shareholding Notification
2024-01-25 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 11, 2024, by Zura Bio Limited. It specifically mentions that the filing includes an Investor Presentation as Exhibit 99.1, which is incorporated by reference and used for presentations to banks and analysts. The text clarifies that the presentation is summary information intended for investors and analysts and is not considered "filed" under the Exchange Act unless specifically stated. The document is not the presentation itself but a current report announcing and furnishing the Investor Presentation. The length is about 5072 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP) filing type, as it primarily concerns the dissemination of an investor presentation to the public and regulators.
2024-01-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-01-08 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 3, 2024, by Zura Bio Limited. The content focuses on the departure of a Chief Medical Officer and Executive Vice President, and the appointment of a new President and Chief Operating Officer, including details about the new executive's background, employment agreement, and stock options. There is no financial data or comprehensive financial reporting. The document is clearly an announcement of changes in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length (9641 characters) is sufficient to contain detailed information, not just a brief announcement or a report publication notice. Hence, the classification is MANG with high confidence.
2024-01-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.